Stockscreener 앱 받기
0.8556
1.50%
-0.013
시간 외 거래:
.88
0.0244
+2.85%
전일 마감가:
$0.8686
열려 있는:
$0.88
하루 거래량:
501.63K
Relative Volume:
1.14
시가총액:
$9.97M
수익:
$37.17M
순이익/손실:
$-17.57M
주가수익비율:
-0.4708
EPS:
-1.8172
순현금흐름:
$-12.01M
1주 성능:
-1.66%
1개월 성능:
-0.50%
6개월 성능:
-4.93%
1년 성능:
-14.44%
1일 변동 폭
$0.78
$0.9601
1주일 범위
$0.78
$0.9601
52주 변동 폭
$0.536
$1.19
Biofrontera Inc Stock (BFRI) Company Profile
명칭
Biofrontera Inc
전화
781-245-1325
주소
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.8556 | 10.12M | 37.17M | -17.57M | -12.01M | -1.8172 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Biofrontera Inc 주식(BFRI)의 최신 뉴스
Biofrontera 2025 Financial Results: Record Annual & Quarterly RevenueNews and Statistics - IndexBox
Biofrontera (BFRI) Q4 2025 Financial Results Transcript - Bitget
Biofrontera (BFRI) Q4 2025 Earnings Transcript - The Globe and Mail
BFRI: Record revenue, improved margins, and clinical progress set up strong 2026 growth - TradingView
Earnings call transcript: Biofrontera Inc. Q4 2025 sees record revenue growth - Investing.com UK
Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year - TipRanks
Biofrontera reports record Q4 revenue $17.1M, Q4 gross margin 82.4% and Q4 net income $5.6M - TradingView
Record Q4 for Biofrontera (NASDAQ: BFRI) with 36% revenue growth - Stock Titan
Biofrontera turns Q4 profitable after cutting Ameluz earnout payments - Stock Titan
Price Action: Does Biofrontera Inc have a sustainable dividend2026 Pullbacks & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Nasdaq Moves: Does Biofrontera Inc Equity Warrant have pricing power2026 Snapshot & Real-Time Chart Breakout Alerts - baoquankhu1.vn
BFRIW SEC FilingsBiofrontera 10-K, 10-Q, 8-K Forms - Stock Titan
Biofrontera Inc expected to post earnings of 20 cents a shareEarnings Preview - TradingView
BFRIWBiofrontera Latest Stock News & Market Updates - Stock Titan
Analysts Offer Insights on Healthcare Companies: OS Therapies Incorporated (OSTX), Legend Biotech (LEGN) and Biofrontera (BFRI) - The Globe and Mail
Biofrontera (BFRI) to Release Earnings on Thursday - Defense World
Are healthcare shares trailing behind Align Technology (ALGN) in performance this year? - Bitget
PTA-Adhoc: Biofrontera AG: Financial Guidance for FY 2026 - TradingView
Market Rankings: Is Biofrontera Inc backed by strong institutional buying2026 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Bitget
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - The Manila Times
Biofrontera Inc. to Report Fourth Quarter and Full Year - GlobeNewswire
Biofrontera reports Phase 2b acne trial results for Ameluz PDT - Investing.com India
Biofrontera Reports Positive Phase 2b Acne Trial Results - TipRanks
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - The Manila Times
Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView
Biofrontera Inc. Reports Positive Phase 2b Results - GlobeNewswire
Is Biofrontera Inc. backed by strong institutional buyingQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Loss Report: Does Biofrontera Inc have a sustainable dividendDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Biofrontera Inc. (BFRI) CFO granted RSUs, options and stock conversion - Stock Titan
Biofrontera (NASDAQ: BFRI) director gets 20,000 stock options - Stock Titan
BFRIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Biofrontera Inc. stock go up in YEAR2025 Top Gainers & Risk Controlled Stock Alerts - mfd.ru
Bank Watch: Is Biofrontera Inc a play on infrastructure spendingJuly 2025 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn
Biofrontera wins patent ruling against Sun Pharma in dispute By Investing.com - Investing.com Canada
Biofrontera wins patent ruling against Sun Pharma in dispute - Investing.com
Biofrontera reports USPTO decision on Sun Pharma’s challenged claims - TipRanks
Biofrontera Wins Key PTAB Ruling in Sun Patent Dispute - TipRanks
Biofrontera (NASDAQ: BFRI) wins PTAB decision on Sun Pharma patent claims - Stock Titan
U.S. Patent Office Issues Final Written Decision Finding - GlobeNewswire
Gains Recap: Will Biofrontera Inc stock go up in YEAR2025 Trading Recap & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Is Biofrontera Inc. stock technically oversoldWeekly Stock Analysis & Community Consensus Trade Signals - mfd.ru
Growth Value: Can Biofrontera Inc Equity Warrant sustain its profitabilityLong Setup & Weekly Breakout Watchlists - baoquankhu1.vn
BFRIBiofrontera Inc Latest Stock News & Market Updates - Stock Titan
Trading Action: Does Biofrontera Inc have high return on assets2025 Risk Factors & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Can Biofrontera Inc Equity Warrant sustain its profitabilityMarket Growth Report & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
How Biofrontera Inc. Equity Warrant stock responds to policy changesJuly 2025 Retail & Low Drawdown Momentum Ideas - mfd.ru
Fundamentals Check: Can Biofrontera Inc Equity Warrant navigate macro headwindsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Biofrontera completes key study for Ameluz skin treatment expansion By Investing.com - Investing.com South Africa
Biofrontera Emerges as Stronger Biotech Stock Compared to RenovaCare - National Today
Biofrontera completes key study for Ameluz skin treatment expansion - Investing.com
Biofrontera Inc (BFRI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):